Tofflon(SZ:300171) Xin Lang Zheng Quan·2025-11-13 02:02Core Viewpoint - Dongfulong's stock price has shown a significant increase of 29.49% year-to-date, despite a slight decline of 0.18% in the last five trading days, indicating a volatile but generally positive market performance [1][2]. Financial Performance - For the period from January to September 2025, Dongfulong achieved a revenue of 3.704 billion yuan, reflecting a year-on-year growth of 6.14%. However, the net profit attributable to shareholders decreased by 13.86% to 132 million yuan [2]. - Cumulative cash dividends since the A-share listing amount to 1.782 billion yuan, with 512 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.14% to 31,400, while the average circulating shares per person increased by 2.19% to 17,910 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 888,200 shares to 8.2218 million shares, and Southern CSI 1000 ETF, which reduced its holdings by 48,600 shares to 3.5016 million shares [3]. Market Activity - On November 13, Dongfulong's stock rose by 2.03% to 17.06 yuan per share, with a trading volume of 49.4883 million yuan and a turnover rate of 0.52%. The total market capitalization stands at 13.065 billion yuan [1]. - The net inflow of main funds was 2.2165 million yuan, with large orders accounting for 18.00% of purchases and 13.52% of sales [1]. Business Overview - Dongfulong Technology Group Co., Ltd. specializes in the research, design, production, sales, and service of medical freeze-dry machines and systems. The revenue breakdown shows that the formulation division contributes 44.92%, the bioprocess division 29.83%, the engineering division 9.19%, the food division 9.16%, and after-sales service and parts 6.81% [1]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices [1].